Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 15/07/2024 pm IST			5-day change	1st Jan Change
973.3 ^DKK	-0.71%		-1.15%	+39.42%

15/07	Health Care Declines on Regulatory Fears - Health Care Roundup	DJ
15/07	European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO	MT

NOVO NORDISK : Goldman Sachs reiterates its Buy rating

July 11, 2024 at 01:35 pm IST

In a research note published by James Quigley, Goldman Sachs advises its customers to buy the stock. The target price remains unchanged at DKK 1070.

Latest news about Novo Nordisk A/S

Health Care Declines on Regulatory Fears - Health Care Roundup	16/07	DJ
European Equities Close Lower in Monday Trading; Luxury Goods Stocks Fall as Burberry Reports 'Disappointing' Q1 Results, Fires CEO	15/07	MT
Novo Nordisk Says No Meeting Scheduled With US Senate Aides, Senior Executives	15/07	MT
Novo Nordisk Reported to Meet Senate Staff Over Decision to Discontinue Levemir Insulin	15/07	MT
Novo Nordisk Denies Reported Meeting with US Senate Aides Over Insulin Discontinuation	15/07	MT
Novo Nordisk to Meet US Senate Aides Over Levemir Insulin Sales Halt	15/07	MT
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	12/07	RE
European Equities Close Higher in Friday Trading; Unilever to Cut 3,200 European Jobs	12/07	MT
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	12/07	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	12/07	RE
Novo Nordisk's Ozempic Reduces Dementia and Cognitive Risks, Oxford Study Says	12/07	MT
NOVO NORDISK : Buy rating from Deutsche Bank	12/07	ZD
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
European Equities Close Higher Thursday; UK GDP Grows More Than Expected	11/07	MT
Global markets live: Tesla, Citigroup, BP, Novo Nordisk, JPMorgan...	11/07
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	11/07	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	11/07	MT
Novo Nordisk Partners with Bio Farma to Package Insulin in Indonesia	11/07	MT
Pfizer moves forward with once-daily weight loss drug	11/07	RE
Novo Nordisk Gets Complete Response Letter from US FDA for Insulin Icodec Application	11/07	MT
NOVO NORDISK : Goldman Sachs reiterates its Buy rating	11/07	ZD
NOVO NORDISK : JP Morgan reaffirms its Buy rating	11/07	ZD
Gerresheimer core profit meets forecast on weight-loss drug deals pipeline	11/07	RE
Novo Nordisk: FDA applications for icodec	11/07	CF

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 10:06 pm IST

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 09:39 pm IST

Novo Nordisk doesn't disappoint

January 31, 2024 at 09:18 pm IST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

973.3 DKK

Average target price

956.5 DKK

Spread / Average Target

-1.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+39.42%	636B
ELI LILLY AND COMPANY	+63.05%	854B
JOHNSON & JOHNSON	-4.78%	361B
MERCK & CO., INC.	+17.52%	324B
ABBVIE INC.	+8.43%	301B
ASTRAZENECA PLC	+14.19%	247B
ROCHE HOLDING AG	+5.81%	230B
NOVARTIS AG	+16.77%	228B
AMGEN INC.	+14.63%	177B
PFIZER, INC.	+1.08%	164B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Goldman Sachs reiterates its Buy rating

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals